Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Upstream Bio, Inc.

Get SEC filing alerts via email and in your feed for Upstream Bio, Inc.

UPB

Upstream Bio, Inc.

About Upstream Bio, Inc.

Upstream Bio, Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, focusing on severe respiratory conditions. Its lead candidate, verekitug, is a monoclonal antibody targeting the TSLP receptor to treat asthma, CRSwNP, and COPD. The company aims to improve clinical outcomes with extended dosing intervals, addressing unmet needs in immune-mediated diseases through innovative biologics.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Upstream Bio, Inc.

1
1
Upstream Bio, Inc. Upstream Bio Reports $1M Collaboration Revenue, $40.6M Net Loss in Q1 2026

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Upstream Bio, Inc. Upstream Bio Reports $143.4 Million Net Loss for 2025 Amid Increased R&D Expenses

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Upstream Bio, Inc. Upstream Bio Reports $33.7 Million Net Loss in Q3 2025, Increased R&D Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Upstream Bio, Inc. Upstream Bio Reports $39.97 Million Net Loss in Q2 2025 Amid Increased R&D Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Upstream Bio, Inc. Upstream Bio Reports $27.3 Million Net Loss in Q1 2025, Increased R&D Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments